PDF(Pubmed)
Abstract：
Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current therapeutic options. Neovascularisation development during the course of the disease has a complex pathogenetic mechanism, and several biomarkers and their association with treatment outcomes have been investigated. We reviewed the relevant literature about neovascularisation development and biomarkers related to response to treatment. Improving our knowledge on the field can improve patient outcomes and offer personalised care.
摘要：
年龄相关性黄斑变性是导致失明的主要原因,抗血管内皮生长因子（VEGF）玻璃体内治疗的发展彻底改变了该疾病的管理。同时,由于当前治疗方案的局限性,出现了新的挑战和未满足的需求.疾病过程中的新生血管形成发展具有复杂的发病机制，研究了几种生物标志物及其与治疗结果的关系。我们回顾了有关新血管形成发展和与治疗反应相关的生物标志物的相关文献。提高我们在该领域的知识可以改善患者的治疗效果并提供个性化护理。
